Josiah Baker, PA
Orthopaedic Surgery · Lancaster, PANPI 1336742717
Payments from drug & device makers
Across 421 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$971
- AbbVie$744
- Bayer$634
- Pfizer$625
- Lilly USA, LLC$578
- plus $3K from 23 others
What the payments were for
- Food & beverage$7,67998%
- Education$1552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 71 | $1,321 |
| AstraZeneca | 41 | $971 |
| AbbVie | 46 | $744 |
| Bayer | 37 | $634 |
| Pfizer | 36 | $625 |
| Lilly USA, LLC | 44 | $578 |
| Boehringer Ingelheim | 27 | $538 |
| Astellas Pharma US Inc | 8 | $295 |
| Amgen | 15 | $236 |
| Novartis | 10 | $214 |
| Esperion Therapeutics, Inc. | 7 | $190 |
| GSK | 10 | $174 |
| Merck | 10 | $170 |
| Teva Pharmaceuticals USA, Inc. | 8 | $164 |
| Sanofi-aventis U.S. LLC | 9 | $154 |
| Lexicon Pharmaceuticals, Inc. | 2 | $147 |
| Amarin Pharma, Inc. | 7 | $106 |
| Johnson & Johnson | 7 | $104 |
| Actelion Pharmaceuticals US, Inc. | 5 | $94 |
| Lundbeck LLC | 3 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $60 |
| Sumitomo Pharma America, Inc. | 3 | $59 |
| Sunovion Pharmaceuticals Inc. | 3 | $36 |
| Abbott | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Corcept Therapeutics | 2 | $32 |
| Biogen | 1 | $24 |
| Exact Sciences | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,834 in reported general payments places this provider in the 60th percentile of 1,048 orthopaedic surgery providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 71 | $72,630 |
| OzempicSemaglutide | 36 | $39,576 |
| EliquisApixaban | 25 | $33,360 |
| FarxigaDapagliflozin Propanediol | 38 | $32,073 |
| TrulicityDulaglutide | 25 | $28,721 |
| RybelsusSemaglutide | 12 | $22,952 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $19,951 |
| MounjaroTirzepatide | 18 | $18,416 |
| KerendiaFinerenone | 16 | $12,790 |
| XareltoRivaroxaban | 11 | $11,524 |
| JanuviaSitagliptin Phosphate | 13 | $9,498 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $8,606 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,397 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,605 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $3,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $538 | $72,63071 claims |
| Novo NordiskOzempic, Rybelsus | $1,321 | $62,52848 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $578 | $47,13743 claims |
| PfizerEliquis | $625 | $33,36025 claims |
| AstraZenecaFarxiga | $971 | $32,07338 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $154 | $19,95120 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $174 | $14,00227 claims |
| BayerKerendia | $634 | $12,79016 claims |
| Johnson & JohnsonXarelto | $104 | $11,52411 claims |
| MerckJanuvia | $170 | $9,49813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,048 orthopaedic surgery providers in Pennsylvania.
Other orthopaedic surgery in Lancaster
- Michael BercikLancaster$214K
- William HozackBensalem$10.6M
- Jess LonnerBryn Mawr$8.1M
- Gerald WilliamsBryn Mawr$6.8M
- Mark LazarusBensalem$6.4M
- John FenlinPhiladelphia$5.9M
- Peter SharkeyKing Of Prussia$5.7M
- Selene ParekhBensalem$4.9M
- Alexander VaccaroPhiladelphia$4.5M
- Joseph AbboudPhiladelphia$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.